A stupendous 93% reduction in 3-yr diabetes incidence risk. 0.07 Hazard ratio for diabetes of Tirzepatide (dual GIP/GLP1-R agonist) in patients with obesity. Drug effects of this magnitude outside of preventative ID vaccines are absolutely wild. www.nejm.org/doi/full/10....

5 likes 1 replies